Filing Flows › Coherus Oncology (CHRS) › Q1 2026
Coherus Oncology (CHRS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
Coherus Oncology (CHRS) reported revenue of $12.3M for the first quarter 2026 (Q1 2026), +62% from a year earlier and -3% from the quarter before. Operating margin was -293.7%, net loss $38.3M (311.3% of revenue).
Coherus Oncology, Q1 2026: revenue $12.3M (+62% year over year), operating margin -293.7%, net loss $38.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.3M | -3% | +62% |
| Operating profit | −$36.2M | — | — |
| Net earnings | −$38.3M | — | — |
| Operating cash flow | −$57.9M | — | — |
What changed
Revenue was $12.3M in Q1 2026, up 62% year over year and down 3% from the previous quarter. Toripalimab was the largest line at 96% of revenue. Toripalimab added $4.5M year over year (up 61%), 95% of the total change.
Operating costs exceeded revenue by $36.2M, an operating margin of -293.7%. Total costs fell 9% while revenue rose 62%. The fastest-growing cost line was Cost of revenue (+44%). The quarter ended with a net loss of $38.3M, wider than the previous quarter's $37.6M loss.
Operating cash flow was −$57.9M. Non-cash charges added back $881K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $22.8M.
Questions
What was Coherus Oncology's revenue in the first quarter 2026?
Coherus Oncology (CHRS) reported revenue of $12.3M for the first quarter 2026 (Q1 2026), +62% from a year earlier and -3% from the quarter before.
Was Coherus Oncology profitable in the first quarter 2026?
Operating loss was $36.2M (-293.7% of revenue) and net loss $38.3M.
Source: Coherus Oncology 10-Q on SEC EDGAR.